Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (101-110 of 192) with videos related to

Pageof 20
Sort By:
Thoracic Cancer|February 24, 2018
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1Toru Kumagai, Yasuhiko Tomita, Shin-Ichi Nakatsuka, et al.
Clinical Lung Cancer|January 2, 2013
Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancerMotohiro Tamiya, Shinya Tokunaga, Hideaki Okada, et al.
Lung|October 22, 2013
Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysisHidekazu Suzuki, Kazuhiro Asami, Tomonori Hirashima, et al.
JTO Clinical and Research Reports|November 29, 2023
Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLCYuhei Kinehara, Takayuki Shiroyama, Akihiro Tamiya, et al.
JTO Clinical and Research Reports|June 7, 2023
Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLCTomoki Kuge, Takayuki Shiroyama, Akihiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2022
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitisTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Anticancer Research|July 3, 2019
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 2015
[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)]Kaori Iwata, Noriko Ryota, Ami Hikita, et al.
Medical Oncology (Northwood, London, England)|January 25, 2015
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutationsAkihiro Tamiya, Motohiro Tamiya, Takayuki Shiroyama, et al.
Targeted Oncology|July 11, 2024
Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World StudyKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 20

Showing results (101-110 of 192) with videos related to

Sort By:
Pageof 20
Thoracic Cancer|February 24, 2018
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1Toru Kumagai, Yasuhiko Tomita, Shin-Ichi Nakatsuka, et al.
Clinical Lung Cancer|January 2, 2013
Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancerMotohiro Tamiya, Shinya Tokunaga, Hideaki Okada, et al.
Lung|October 22, 2013
Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysisHidekazu Suzuki, Kazuhiro Asami, Tomonori Hirashima, et al.
JTO Clinical and Research Reports|November 29, 2023
Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLCYuhei Kinehara, Takayuki Shiroyama, Akihiro Tamiya, et al.
JTO Clinical and Research Reports|June 7, 2023
Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLCTomoki Kuge, Takayuki Shiroyama, Akihiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2022
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitisTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Anticancer Research|July 3, 2019
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 2015
[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)]Kaori Iwata, Noriko Ryota, Ami Hikita, et al.
Medical Oncology (Northwood, London, England)|January 25, 2015
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutationsAkihiro Tamiya, Motohiro Tamiya, Takayuki Shiroyama, et al.
Targeted Oncology|July 11, 2024
Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World StudyKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 20